Kanglaite upregulates CD4+ T cells by inhibiting the expression of IL-1β in A549 cells
Abstract
Background: Superior clinical efficacy and safety have been demonstrated in Kanglaite combined with cisplatin compared with cisplatin- or Kanglaite-alone treatment on advanced non-small cell lung cancer (NSCLC). However, the mechanism of how Kanglaite enhances antitumor effect of cisplatin is not fully addressed.
Methods: An A549 tumor-bearing mouse model was applied in this study. The tumor-bearing mice were treated with 0.9% saline, Kanglaite-alone, cisplatin-alone, or Kanglaite and cisplatin combination. Immune cell population was determined by flow cytometry assay. The production of cytokine was measured by ELISA assay.
Results: The results demonstrated that Kanglaite and cisplatin combination treatment exerted the most potent effects on reducing tumor growth and prolonging mouse survival. Further studies revealed that the upregulation of CD4+ T cells and downregulation of IL-1β might be responsible for the Kanglaite-promoted antitumor effect of cisplatin on A549 tumor.
Conclusion: Kanglaite serves as an excellent supplement for cisplatin in treating patients with advanced NSCLC.
Downloads
References
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011; 32: 605–44. doi: 10.1016/j.ccm.2011.09.001
Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 2015; 3: 217–21. doi: 10.3892/mco.2014.410
Rami-Porta R, Eberhardt WEE. Clinical implications of the innovations in the primary tumour and metastasis of the 8(th) edition of the TNM classification for lung cancer. J Thorac Dis 2018; 10: S2682–5. doi: 10.21037/jtd.2018.03.100
Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Exp Rev Anticancer Ther 2016; 16: 653–60. doi: 10.1586/14737140.2016.1170596
D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926–36. doi: 10.1200/JCO.2005.03.045
Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, et al. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol 2015; 75: 521–6. doi: 10.1007/s00280-014-2670-y
Zhu L, Yang Z, Wang S, Tang Y. [Kanglaite for treating advanced non-small-cell lung cancer: a systematic review]. Zhongguo Fei Ai Za Zhi 2009; 12: 208–15.
Huang X, Wang J, Lin W, Zhang N, Du J, Long Z, et al. Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of 27 RCTs. Phytomedicine 2020; 67: 153154. doi: 10.1016/j.phymed.2019.153154
Liu X, Xu F, Wang G, Diao X, Li Y. Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: a systematic review and meta-analysis. Curr Ther Res Clin Exp 2008; 69: 381–411. doi: 10.1016/j.curtheres.2008.10.004
Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. PLoS One 2017; 12: e0184360. doi: 10.1371/journal.pone.0184360
Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine 2017; 7: 23. doi: 10.1051/bmdcn/2017070423
Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One 2013; 8: e60338. doi: 10.1371/journal.pone.0060338
Zhang X, Qiu H, Li C, Cai P, Qi F. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends 2021; 15(5): 283–98. doi: 10.5582/bst.2021.01318
Gao R, Zhang Y, Hou W, Li J, Zhu G, Zhang X, et al. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial. Trials 2021; 22: 214. doi: 10.1186/s13063-021-05169-w
Wen J, Yang T, Wang J, Ma X, Tong Y, Zhao Y. Kanglaite injection combined with chemotherapy versus chemotherapy alone for the improvement of clinical efficacy and immune function in patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2020; 2020: 8586596. doi: 10.1155/2020/8586596
Kong F, Wang C, Li X, Jia Y. Kanglaite combined with epidermal growth factor receptor-tyrosine kinase inhibitor therapy for stage III/IV non-small cell lung cancer: a PRISMA-compliant meta-analysis. Front Pharmacol 2021; 12: 739843. doi: 10.3389/fphar.2021.739843
Qin ZF, Wei PK, Li J. [Effect of kanglaite injection combined with Chinese drug therapy according to syndrome differentiation on quality of life and immune function in patients with advanced lung cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002; 22: 618–19.
Liu J, Yu L, Ding W. Efficacy and safety of Kanglaite injection combined with radiochemotherapy in the treatment of advanced pancreatic cancer: a PRISMA-compliant meta-analysis. Medicine 2019; 98: e16656. doi: 10.1097/MD.0000000000016656
Zhan YP, Huang XE, Cao J, Lu YY, Wu XY, Liu J, et al. Clinical safety and efficacy of Kanglaite(R) (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev 2012; 13: 5319–21. doi: 10.7314/APJCP.2012.13.10.5319
Liu S, Wang H, Wang M, Hu X, Yang W, Jin R, et al. Comparative efficacy and safety of Chinese herbal injections combined with cyclophosphamide and 5-fluorouracil chemotherapies in treatment of breast cancer: a Bayesian network meta-analysis. Front Pharmacol 2020; 11: 572396. doi: 10.3389/fphar.2020.572396
Huang X, Qin J, Lu S. Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantationinduced tumor growth. Mol Med Rep 2014; 10: 2153–9. doi: 10.3892/mmr.2014.2479
Copyright (c) 2022 Chenggong Li, Yigeng Feng
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain full copyright to their individual works, and publishing rights without restrictions.
In accordance with the Budapest Open Access Initiative, articles published in STEMedicine are freely available "on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited."
Except where otherwise noted, all content on this website is licensed under a Creative Commons Attribution 4.0 License. This license allows for commercial and non-commercial redistribution as well as modifications of the work as long as attribution is given to the authors and STEMedicine as the original publication source, and a link to the article on the STEMedicine website is provided.
